Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bagegni

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Cancer Chemotherapy and Pharmacology|March 5, 2022
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumorsNusayba A Bagegni, Haeseong Park, Katlyn Kraft, et al.
Advances in Radiation Oncology|March 5, 2021
Radiation-Induced Brachial Plexopathy in Patients With Breast Cancer Treated With Comprehensive Adjuvant Radiation TherapySoumon Rudra, Amit Roy, Randall Brenneman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of diseaseG Curigliano, X Hu, R Dent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast CancerWhitney L Hensing, Lorenzo Gerratana, Katherine Clifton, et al.
Ebiomedicine|November 4, 2022
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancerAndrew A Davis, Lorenzo Gerratana, Katherine Clifton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trialM P Goetz, N A Bagegni, G Batist, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cancer Chemotherapy and Pharmacology|March 5, 2022
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumorsNusayba A Bagegni, Haeseong Park, Katlyn Kraft, et al.
Advances in Radiation Oncology|March 5, 2021
Radiation-Induced Brachial Plexopathy in Patients With Breast Cancer Treated With Comprehensive Adjuvant Radiation TherapySoumon Rudra, Amit Roy, Randall Brenneman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of diseaseG Curigliano, X Hu, R Dent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast CancerWhitney L Hensing, Lorenzo Gerratana, Katherine Clifton, et al.
Ebiomedicine|November 4, 2022
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancerAndrew A Davis, Lorenzo Gerratana, Katherine Clifton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trialM P Goetz, N A Bagegni, G Batist, et al.
Pageof 2